We have shown that deregulated expression of either c-Myb or E2F-1 blocks terminal differentiation of M1 myeloid leukemia cells at the blast stage, whereas deregulated c-Myc blocks differentiation at the intermediate stage. Each of these oncogenes potentiates M1 leukemia in vivo. The zinc-finger transcription factor Egr-1 abrogates the block in M1 terminal differentiation imparted by oncogenic c-Myc or E2F-1, suppressing their leukemia-promoting function in nude mice. In this study, we asked whether Egr-1 also abrogates the block in terminal differentiation and suppresses leukemia imparted by deregulated c-Myb. Interestingly, the ectopic expression of Egr-1 in M1 cells expressing deregulated c-Myb only partially abrogated the block in terminal differentiation and did not suppress the leukemic phenotype. Two important implications from these data are that the leukemia suppressor function of Egr-1 is not directly related to how early the transforming oncogene blocks the differentiation program and that the tumor suppressor function of Egr-1 is dependent on the specific oncogene. Egr-1 is dominant to c-Myc-and E2F-1-, but not to c-Myb-, driven leukemia. These findings extend the notion that the molecular nature of genetic lesions responsible for leukemia determines the effectiveness of any given tumor suppressor.
Introduction
Blocks in both terminal myeloid differentiation and the apoptotic response that follows maturation participate in the progression toward leukemia; this can occur by overexpression of negative regulators or inhibition of positive regulators of differentiation. Manipulating cells by biological and/or chemical means to overcome the block in differentiation and/or apoptosis would effectively eliminate the leukemic cells. The autonomously proliferating M1 myeloblastic leukemia cell line is induced by interleukin-6 (IL-6) to undergo terminal macrophage differentiation followed by apoptosis with concomitant loss of leukemogenicity, providing an attractive model system to analyze the different regulators of terminal differentiation and to assess potential tumor suppressors. Using the M1 cell line, this laboratory has shown that the protooncogenes c-myc and c-myb and the transcription factor E2F-1 are negative regulators, and Egr-1 is a positive regulator of terminal myeloid differentiation. [1] [2] [3] [4] [5] The early growth response gene 1 (egr-1), a macrophage differentiation primary response gene, has been shown to be essential for and to restrict differentiation along the macrophage lineage. 4 Ectopic Egr-1 expression potentiated macrophage differentiation of the hematopoietic precursor cell line 32Dcl3, and stimulated the development of bone-marrow-derived hematopoietic progenitor cells along the macrophage lineage at the expense of granulocyte and erythroid lineages. 6, 7 The deregulated expression of Egr-1 in the M1 cell line activated the macrophage differentiation program in the absence of differentiation inducer. 3 Consistent with these findings, Laslo et al. 8 have demonstrated that Egr-1 and Egr-2 are major positive modulators of macrophage differentiation under the direction of the primary transcription factor PU.1. Deregulated c-Myc expression in M1 myeloid leukemic cells blocks IL-6-induced differentiation at an intermediate stage, the cells fail to exit the cell cycle, proliferating indefinitely, and continue to be leukemogenic. Egr-1 expression in M1Myc cells abrogates the block in terminal differentiation imparted by c-Myc, resulting in cells that have the characteristics of functionally mature macrophages that undergo apoptosis without arresting in G0/G1 phase, and also abrogates the leukemic potential of IL-6-treated M1Myc cells. 9 In contrast to the observed effects of deregulated c-Myc expression, deregulated expression of E2F-1, a pivotal transcription factor for the transition through the G1/S phase of the cell cycle, blocks terminal myeloid differentiation at an early, blast-like stage, and also prevents the loss of leukemogenicity after the IL-6 treatment of M1 cells.
1 Egr-1 expression in M1E2F-1 cells overcomes the block in terminal myeloid differentiation, abrogates E2F-1-driven leukemogenicity, and, unlike cells concomitantly expressing c-Myc and Egr-1, also becomes G0/G1 arrested. 10 These observations are consistent with egr-1 behaving like a tumor suppressor gene in myeloid cells, promoting differentiation in cells with deregulated expression of either c-Myc or E2F-1.
Interestingly, the human egr-1 gene was localized to the q region of chromosome 5, where either deletion or monosomy is frequently observed in patients with myelodysplastic syndromes or acute myeloid leukemia. 11, 12 Consistent with egr-1 being a tumor suppressor gene, it was recently shown that haploinsufficiency of egr-1 cooperates with mutations induced by alkylating agents in the development of malignant lymphoid and myeloid diseases in mice. 13 Continued assessment of Egr-1 expression in patients with either myelodysplasia or acute myeloid leukemia at the time of diagnosis and during the course of treatment should further correlate Egr-1 expression levels to outcome after treatment.
C-Myb is a transcription factor that is crucial for normal hematopoietic development, and its inappropriate expression is common in leukemias. 14 Recently, it was shown that leukemic transformation by either BcrAbl or MLL-ENL oncoproteins is dependent on c-Myb expression, 15, 16 and that proliferation of leukemic cells can be inhibiting by blocking c-Myb expression. 17 Deregulated expression of c-Myb blocks IL-6-induced differentiation of M1 cells at the morphologically immature stage, and prevents the loss in leukemogenicity, similar to deregulated E2F-1.
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As Egr-1 functions as a tumor suppressor in myeloid cells with deregulated c-Myc or E2F-1, and c-Myb expression is an important determinant in the generation and maintenance of leukemia, it was asked whether Egr-1 can also function as a tumor suppressor in myeloid cells expressing deregulated c-Myb. In this study, it is shown that when Egr-1 was coexpressed with the protooncogene c-myb in M1 cells, the block in differentiation was only partially alleviated and the cells continued to proliferate indefinitely. In addition, there was no effect on the leukemogenic property of IL-6-treated M1Myb/ Egr-1. This is in stark contrast to the tumor-suppressing effect of Egr-1 on c-Myc-or E2F-1-expressing cells, consistent with the notion that for a specific cell type the effectiveness of any given tumor suppressor is determined by the genetic lesions responsible for the tumor.
Materials and methods

Cells, culture, cytokines and mice
The M1 murine myeloblastic leukemia cell line was previously described. 9 Stably transduced M1Egr-1 and M1Myb cell lines were similarly cultured with the addition of G418 (200 mg/ml) or puromycin (2 mg/ml) to maintain selection of the transgenes. To induce differentiation, cells were treated with 50 ng/ml of purified recombinant human IL-6 (Amgen, Thousand Oaks, CA, USA) after being seeded at a concentration of 1 Â 10 5 cells per milliliter. Eight-week-old CD-1 nu/nu mice were used (Charles River Laboratories, Wilmington, MA, USA).
Establishment of M1 cell line that ectopically expresses both Egr-1 and c-Myb transgenes
Cell lines were established as previously described. 9 Several independent M1Myb/Egr-1 clones were characterized for the level of expression of their transgenes. Initially, five clones were found to behave similarly. More extensive analysis was carried out using two of the clones throughout this study, and gave comparable results. Control cell lines were indistinguishable from their respective parental controls.
General recombinant DNA techniques and expression vectors
Plasmids, DNA probes and MSCV-puro-Egr-1 3,9,10 were previously described.
Analysis of cell morphology
A total of 250-300 cells were assessed, scoring the proportion of immature blast cells (characterized by scant cytoplasm and round or oval nuclei), cells at intermediate stages of differentiation (flattened, with a larger cytoplasm-to-nucleus ratio, and irregularly shaped nuclei with few interspersed vacuoles) and mature macrophages (flattened, spread out and interspersed with numerous vacuoles in a greatly enlarged cytoplasm).
3,9
Phagocytosis analysis Cells were seeded at 1 Â 10 5 cells per milliliter with or without IL-6 (50 ng/ml). The night before harvesting, latex beads (3.0 mm in size Fluoresbrite YG latex beads, Polyscience, Warrington, PA, USA; 150 beads per cell) were added. At indicated times, cells were centrifuged (10 min, 2000 r.p.m.), cell pellets were fixed in ethanol counterstained with Alexa Fluor 568 palloidin (Molecular Probes, Eugene, OR, USA) for F-actin and a nuclear dye, Hoechst (Molecular Probes). Cells, mounted on slides, were analyzed by fluorescent microscopy using an Olympus AH-3 microscope (Â 40/0.7 NA (numerical aperture) objective with filters for FITC (fluorescein isothiocyanate), Texas Red and DAPI (4 0 ,6-diamidino-2-phenylindole)). Images were acquired through an Insight camera using imaging software SPOT. Latex beads are visualized with the FITC filter, F-actin with the Texas Red filter and nuclei with the DAPI filter. To quantify phagocytic cells, cells were subjected to flow cytometry (BD FACSCalibur) using Cell Quest Pro 5.2 software (Becton Dickinson, San Jose, CA, USA).
Analysis of apoptosis by Annexin/propidium iodide
Apoptosis associated with terminal myeloid differentiation was measured using the Annexin V-FITC apoptosis detection kit II along with propidium iodide staining for cell viability, according to the manufacturer's instructions (BD Pharmingen, San Diego, CA, USA), and analyzed by flow cytometry.
RNA extraction, northern blots and probes
RNA extraction, northern blots and probes were carried out as previously described.
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Protein extraction and immunoblotting (western blots)
Protein extraction and immunoblotting were previously described. 3 
Flow cytometry to analyze cell cycle distribution and F4/80 cell surface markers
Cell cycle analysis was carried out as previously described. 3 For F4/80 cell surface marker assessment, cells were labeled with phycoerythrin (PE)-conjugated F4/80 antibody (eBioscience, San Diego, CA, USA) and analyzed by flow cytometry on a BD FACSCalibur along with using Cell Quest Pro 5.2 software (Becton Dickinson).
Assay for leukemia
Eight-week-old CD-1 nu/nu mice were intravenously injected (tail vein) with 10 6 cells suspended in 100 ml phosphate-buffered saline. Control animals were injected with same volume of phosphate-buffered saline.
Statistical analysis
Values are means±s.d. of n independent experiments. Statistical analysis was performed using Student's t-test and the Kaplan-Meier survival curve with the aid of the statistical software SPSS 11.
Results
Establishment of M1Myb/Egr-1 cell lines
The egr-1 transgene was introduced into the M1Myb variant as described in the Materials and methods section. Several M1Myb/Egr-1 clones were analyzed for Egr-1 and Myb mRNA expression ( Figure 1a ) and Egr-1 protein expression (Figure 1b (Figure 3b ).
M1 cells that complete the macrophage differentiation program undergo programmed cell death by 5-7 days. M1 variant and control cells were assessed for apoptosis after treatment with IL-6 for 5 days. Representative data showed a shift of Annexin-V-positive cells for M1 and M1Egr-1, indicating the onset of apoptosis (lower right quadrant) (Figure 4a) . Conversely, only a slight shift of positive cells was observed in M1Myb cells as well as in the M1Myb/Egr-1 cells in the presence of IL-6. The results of three independent experiments revealed that less than 10% of the M1Myb and M1Myb/Egr-1 cells were in the early stage of apoptosis after 5 days in IL-6 (Figure 4b) , in contrast to M1 and M1Egr-1 cells, which have greater than 30% of the population undergoing apoptosis.
Taken together, the data demonstrate that although Egr-1 did not completely override the Myb-mediated block in differentiation, Egr-1 co-expression with c-Myb promoted the cells to differentiate into functionally phagocytic intermediate stage macrophages.
Proliferation and cell cycle analysis of M1Myb/Egr-1 cells
The early block in myeloid differentiation imparted by c-Myb in M1 cells is further demonstrated by the failure of the cells to growth arrest in the presence of IL-6. 5 As Egr-1 co-expression in M1Myb cells promoted the differentiation program to the intermediate stage, it was asked whether M1Myb/Egr-1 cells become growth arrested after IL-6 treatment. As shown in Figure 5a , the M1Myb/Egr-1 cells continued to proliferate, but not as rapidly as M1Myb cells. In addition to M1Myb/Egr-1 clones 10 and 15, several other clones assessed showed similar kinetics. Thus, Egr-1 co-expression in M1Myb cells slowed the growth rate of parental M1Myb cells, but did not promote growth arrest. It should be pointed out that M1Myb and M1Myb/ Egr-1 cells proliferated for at least several weeks in the presence of IL-6 (data not shown). Assessment of distribution of cells in the cell cycle by flow cytometry was consistent with the growth curves, M1Myb/Egr-1 maintaining elevated levels of cells in the S phase, similar to M1Myb after IL-6 treatment and in contrast to M1 and M1Egr-1 cells (Figure 5b) .
As the growth rate of M1Myb/Egr-1 cells treated with IL-6 was less than similarly treated M1Myb cells, it was asked whether there were differences in cell cycle and growth regulators. The expression of key cell cycle regulators was assessed by western blotting after treatment of cells with IL-6. Protein expression of all the positive cell cycle regulators (Cdk2, Cdk4, cyclin D1, cyclin E and cd25A) was downregulated in M1 and M1Egr-1 cells, whereas it was sustained or decreased only marginally in M1Myb cells (Figure 5c ). The M1Myb/Egr-1 cells showed a similar pattern of expression as M1Myb in the presence of IL-6. The expression profile of upstream inhibitors of cdks and cyclins, including, p27 and p21, was assessed (Figure 5d ). p27 was constitutively expressed in all the untreated cell lines, and expression levels were maintained in IL-6-treated M1 and M1Egr-1 cells. In contrast, p27 expression was downregulated in both M1Myb and M1Myb/Egr-1 cells. Additionally, the strong induction of p21 seen in M1 and M1Egr-1 cells was not observed in either M1Myb or M1Myb/Egr-1 cells.
Target genes of Egr-1 that are negative regulators of cell growth, including p35 and TGF-b, 18, 19 were also analyzed. Although no apparent differences were observed in the expression of TGF-b between any of the cell lines, the expression of p35 was altered. A low constitutive expression of p35 was observed in all the untreated cell lines. However, upon treatment with IL-6, p35 was induced in M1Myb/Egr-1 cells similar to the M1 and M1Egr-1 cells (Figure 5d ), whereas very weak induction of p35 in M1Myb cells appeared only by day 4. Interestingly, although the M1Myb/Egr-1 cells continued to cycle when treated with IL-6, the rate of proliferation was slower than in similarly treated M1Myb cells. The observed difference in p35 expression, which has been reported to inhibit the mitogen activated protein kinase (MAPK) pathway, 18 may contribute to this slower growth rate.
Egr-1 expression does not suppress the leukemic phenotype of M1Myb cells treated with IL-6
IL-6-treated M1Myb cells induced leukemia when injected into nude mice, 5 whereas IL-6-treated M1 and M1Egr-1 cells lost their leukemogenic properties. 3 As co-expression of Egr-1 in M1Myb cells stimulated an intermediate stage differentiation and slowed the growth of the cells, it was asked whether the M1Myb/Egr-1 cells continued to be leukemogenic after treatment with IL-6 in culture, and, if so, whether the leukemias are as aggressive as those caused by M1Myb cells. In addition, it was asked whether untreated M1Myb/Egr-1 cells are as effective at killing mice as untreated M1Myb cells.
Approximately 10 6 cells from M1, M1Egr-1, M1Myb and M1Myb/Egr-1 cell lines, treated or untreated with IL-6 for 5 days in vitro, were tail vein-injected into CD-1 nude mice. Survival analysis of the mice was performed using the Kaplan-Meier method. All mice (8 of 8) in each group injected with untreated cells developed leukemia over a period of 3-7 weeks (Figure 6a ). The more aggressive M1Myb cells appeared to induce leukemia more rapidly than the other variants; however, the sample sizes were too small to conclude if the differences between the cell lines were significant. Only controlled animals 
injected with phosphate-buffered saline survived beyond 8 weeks. In all cases, M1 cells were recovered from the bone marrow and had the same properties in vitro as the cells used to inoculate the mice (data not shown). In the IL-6 treatment groups (Figure 6b ), mice injected with either M1 or M1Egr-1 cells were leukemia free and survived beyond 10 weeks. In contrast, animals injected with either M1Myb or M1Myb/Egr-1 cells died by 8 weeks, with no detectable differences in their survival curves, demonstrating that Egr-1 expression in M1Myb cells had no effect on the leukemogenic properties of M1Myb cells.
Myb is downregulated in all M1 variants that undergo terminal differentiation
Both M1Myc/Egr-1 and M1E2F-1/Egr-1 cells became terminally differentiated after treatment with IL-6, 9,10 whereas M1Myb/Egr-1 cells were induced only to the intermediate stage, did not lose viability and continued to proliferate unimpeded. To gain insight into how Egr-1 cells regulate expression of the three oncogenes/ transcription factors that block differentiation, expression of c-Myb, c-Myc and E2F-1 cells was assessed in the different M1 cell variants after treatment with IL-6 (Figure 7a ). Terminal differentiation takes place only in the cells when c-Myb expression is suppressed. C-Myc and E2F-1 expressions do not block differentiation (see M1Myc/Egr-1; Figure 7b ), but c-Myb does when Egr-1 is concomitantly expressed.
Discussion
This study shows that IL-6-treated M1Myb/Egr-1 cells, where the tumor suppressor gene egr-1 is co-expressed with the protooncogene c-myb, differentiated to the intermediate stage and continued to proliferate indefinitely. In addition, there was no detectable difference in the leukemogenic property of IL-6-treated M1Myb/Egr-1 cells compared with M1Myb cells (Figure 7b) .
It was previously shown by this laboratory that Egr-1 behaves as a tumor suppressor by overriding the block in myeloid differentiation caused by either E2F-1 or c-Myc.
9,10 c-Myc blocks myeloid differentiation at the intermediate stage; when Egr-1 is co-expressed with c-Myc in M1 cells, IL-6 induces terminal myeloid differentiation. Although these cells continue to cycle and synthesize DNA while differentiating, the terminally differentiated cells undergo apoptosis, accounting for the loss of the ability to cause leukemia in nude mice. In contrast to the effect of deregulated c-Myc expression in M1 cells, deregulated expression of either E2F-1 or c-Myb blocks IL-6-induced differentiation at the blast stage. Interestingly, co-expression of Egr-1 with each of these oncogenes resulted in a different outcome after treatment with the differentiation inducer IL-6. In contrast to the failure of IL-6 treatment to induce terminal differentiation and growth arrest of M1Myb/Egr-1 cells, IL-6 treatment induced M1E2F-1/Egr-1 cells to terminally differentiate, to undergo G0/G1 arrest and to lose the ability to Egr-1 in suppression of leukemia driven by c-Myc or E2F-1, not c-Myb JD Gibbs et al cause leukemia (Figure 7b ). These data reveal that the leukemia suppressor function of Egr-1 is not directly related to how early the transforming oncogene blocks the differentiation program. Furthermore, they imply that the tumor suppressor function of Egr-1 is dependent on the specific oncogene, where Egr-1 overrides c-myc-and E2F-1-, but not c-myb-, driven leukemia, extending the notion that the molecular nature of genetic lesions responsible for leukemia determines the effectiveness of any given tumor suppressor for the same cell type. Experiments to recapitulate these results using oncogenetransformed myeloid cells derived from bone marrow are currently underway. This study as well as the previous work done by this laboratory reveals that c-Myb is dominant to Egr-1 by preventing terminal differentiation, growth arrest and loss of leukemia. In contrast, c-Myc is only dominant to Egr-1 by preventing growth arrest, allowing Egr-1 to promote differentiation and suppress c-Myc-driven leukemia (Figure 7b ). IL-6-treated M1Myb/Egr-1 cells express both c-Myc and c-Myb, and hence it is possible that in these cells proliferation is mediated through c-Myc (Figure 7a) . Furthermore, it can be seen that c-Myb expression is downregulated whenever M1 cells differentiate, as seen for M1E2F-1/Egr-1 and M1Myc/Egr-1 cells. Interestingly, deregulated expression of c-Myb, in both M1Myb and M1Myb/Egr-1 cells, is accompanied by E2F-1 and c-Myc expression after IL-6 treatment ( Figure 7a ). As noted in the Introduction section, leukemic transformation by either BcrAbl or MLL-ENL oncoproteins is dependent on c-Myb expression, 15, 16 and blocking c-Myb expression inhibits growth of leukemic cells. 17 IL-6-treated M1Myb/Egr-1 cells caused leukemia in nude mice (Figure 6b) , and the cells recovered from the bone marrow of these leukemic mice were myeloblasts (data not shown). The lower concentrations of differentiation factors in vivo may be insufficient to promote an intermediate stage differentiation and/ or reduction in growth rate that were observed in culture. As terminal myeloid differentiation is followed by apoptosis, activating the terminal differentiation program effectively blocks the myeloid leukemia response, as seen for M1Myc/Egr-1 cells. 9 Therefore, it is important to understand the molecular mechanisms that block the terminal differentiation program in M1Myb/ Egr-1 cells.
The uncoupling of terminal myeloid differentiation from cell cycle arrest, seen with M1Myc/Egr-1 cells (Figure7a; Shafarenko et al. 9 and Gibbs et al.
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), eliminates the possibility that the failure of M1Myb/Egr-1 cells to undergo cell cycle arrest accounts for the block in differentiation. Furthermore, the failure of IL-6-treated M1Myb/Egr-1cells to induce p21, an Egr-1 target gene 20 implicated in regulating differentiation rather Figure 6 Leukemia assessment. For each cell type, 10 6 cells, untreated or treated with IL-6 (50 ng/ml) for 5 days, were suspended in 100 ml 1 Â phosphate-buffered saline (PBS) and intravenously (tail vein) injected into eight CD-1 nude mice. Control animals were injected with same volume of 1 Â PBS. Experiment was terminated after 10 weeks. The Kaplan-Meier survival curve of (a) nude mice injected with untreated cells and (b) nude mice injected with IL-6-treated cells. [21] [22] [23] also cannot account for the differentiation block because M1Myc/Egr-1 cells terminally differentiated in the absence of p21 expression. 24 Other target genes of Egr-1 that are potential regulators of hematopoietic development include TGF-b and p35. 18, 19 Chen et al. 18 reported that p35 permitted the onset of the terminal differentiation program of HL-60 cells; however, it is not known how much of a role p35 plays in regulating differentiation and/or growth arrest in these cells. p35 was induced early after IL-6 treatment in M1Myb/Egr-1 cells (Figure 5d Determining the changes in gene and protein expression and post-translational modifications using the established M1 cell variants should provide tools to assess how each of the oncogenes blocks terminal differentiation and how Egr-1 overrides the oncogenic blocks in myeloid differentiation. These studies should provide further insights into how Egr-1 and/or Egr-1 target genes can be used to treat or suppress oncogenedriven hematological malignancies.
